BRCA1 and breast cancer: Several preclinical studies have demonstrated that BRCA1/2-related breast cancer cell lines exhibit varying degrees of sensitivity to chemotherapeutic agents that induce DNA damage, such as poly (ADP-ribose) polymerase (PARP) inhibitors [21].